uspto-grants-1988_07
uspto-grants-1988_07 · 10.6084/m9.figshare.5104873.v1 · US04760064
查看条件与参与物IDENTITY
COMPUTED
PHARMACOLOGY
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
Membrane
ALIASES
REACTIONS
uspto-grants-1988_07
uspto-grants-1988_07 · 10.6084/m9.figshare.5104873.v1 · US04760064
查看条件与参与物uspto-grants-1988_07
uspto-grants-1988_07 · 10.6084/m9.figshare.5104873.v1 · US04760064
查看条件与参与物uspto-grants-1983_11
uspto-grants-1983_11 · 10.6084/m9.figshare.5104873.v1 · US04415572
查看条件与参与物uspto-grants-1983_11
uspto-grants-1983_11 · 10.6084/m9.figshare.5104873.v1 · US04415572
查看条件与参与物